Venatorx Pharmaceuticals is a private pharmaceutical company focused on improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections.
Location: United States, Pennsylvania, Malvern
Employees: 51-200
Total raised: $42M
Founded date: 2010
Investors 4
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | BioAdvance | bioadvance... |
| - | Abingworth... | abingworth... |
| - | CARB-X | carb-x.org |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.07.2017 | Series B | $42M | Foresite C... |
Mentions in press and media 19
| Date | Title | Description |
| 23.05.2024 | New report from Access to Medicine Foundation shows what pharma companies can do to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance | AMSTERDAM, May 23, 2024 /PRNewswire/ -- The race to create replacement antibiotics and antifungals to combat superbugs is falling dangerously short, putting people across the world at risk. However, a shift in research and development (R&am... |
| 09.01.2024 | Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries | MALVERN, Pa. and FLORENCE, Italy, Jan. 9, 2024 /PRNewswire/ -- Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and ha... |
| 15.08.2023 | Everest Medicines' Partner Venatorx Receives FDA Acceptance and Priority Review of New Drug Application for Cefepime-Taniborbactam to Treat Complicated Urinary Tract Infections (cUTI) | SHANGHAI, Aug. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK)'s partner Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for cefepime-tanibo... |
| 04.04.2022 | Big Pharma-backed $1B AMR Action Fund picks 1st antimicrobial biotech investments | The AMR Action Fund, backed by Big Pharmas such as Pfizer, Eli Lilly, Bayer and more, has selected the first beneficiaries of its $1 billion fund to address drug-resistant bacterial infections: Adaptive Phage Therapeutics and Venatorx Pharm... |
| 04.04.2022 | Venatorx Pharmaceuticals Raises Series C Financing | Venatorx Pharmaceuticals, Inc., a Malvern, PA-based private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, sold shar... |
| 10.03.2022 | Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial | SHANGHAI, March 10, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Venatorx Pharmaceuticals, reported positive results from its pivotal Phase 3 study, CERTAIN-1 (Cefepime Rescue with Tanibo... |
| 02.07.2021 | CureVac gains COO and hands Florian von der Mülbe new assignment in the midst of Covid-19 vaccine troubles; As Ken Frazier retires, Merck hires chief strategy officer | Malte Greune → Aiming to bounce back and trying to accentuate the positive after its mRNA Covid-19 vaccine took a major pratfall, CureVac is shaking things up by bringing in Malte Greune as COO and giving new responsibi... |
| 04.08.2020 | Could Drug-Resistant Bacteria Cause The Next Pandemic? | Venetians dressed as plague doctors pose during Carnival in their city's Piazza San Marco on ... [+] February 25, 2020. Their costume dates to the Italian Plague of 1629–1631. (Photo by Giacomo Cosua/NurPhoto via Getty Images)NurPhoto via G... |
| 21.08.2017 | VenatoRx Pharmaceuticals Raises $42M in Series B Funding | VenatoRx Pharmaceuticals, Inc., a Malvern, PA-based biopharmaceutical company developing next‐generation antibiotics, recently raised $42m in Series B financing. The round was led by Versant Ventures with participation from Abingworth, Fore... |
| 26.07.2017 | VenatoRx Pharmaceuticals Nabs $42 Million | MALVERN, PA, VenatoRx Pharmaceuticals, Inc., a biopharmaceutical company developing next-generation antibiotics, today announced that it has raised $42 million in a Series B financing. >> Click here for more funding data on VenatoR... |
Show more